600993 Stock Overview
Engages in the manufacturing and sale of Chinese and Western medicines primarily in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Mayinglong Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.96 |
| 52 Week High | CN¥31.18 |
| 52 Week Low | CN¥21.33 |
| Beta | 0.57 |
| 1 Month Change | -0.48% |
| 3 Month Change | -6.09% |
| 1 Year Change | 8.19% |
| 3 Year Change | 8.95% |
| 5 Year Change | 53.41% |
| Change since IPO | 55.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600993 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.8% | 0.009% | 0.02% |
| 1Y | 8.2% | 4.5% | 18.1% |
Return vs Industry: 600993 exceeded the CN Pharmaceuticals industry which returned 4.5% over the past year.
Return vs Market: 600993 underperformed the CN Market which returned 18.1% over the past year.
Price Volatility
| 600993 volatility | |
|---|---|
| 600993 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 600993 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600993's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1582 | 2,882 | Youzhang Xia | www.mayinglong.cn |
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the manufacturing and sale of Chinese and Western medicines primarily in China. The company provides functional cosmetics, such as eye care, eye daily necessities, facial and body cleaning, and care products; functional care products include infant paper, infant skin care, feminine products, etc.; functional foods, including moisturizing the intestines, promoting digestion, and nourishing the kidneys. It also offers foundation and dietary supplements; medical products comprising anorectal postoperative care, daily electronic auxiliary products, eye device care, disinfection and sterilization, etc. In addition, the company is involved in the development, production, and sale of pharmaceutical products; retail and wholesale of medical devices and drugs; provision of hospital medical and management service; and hospital operations.
Mayinglong Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 600993 fundamental statistics | |
|---|---|
| Market cap | CN¥10.76b |
| Earnings (TTM) | CN¥482.37m |
| Revenue (TTM) | CN¥3.48b |
22.3x
P/E Ratio3.1x
P/S RatioIs 600993 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600993 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.48b |
| Cost of Revenue | CN¥1.90b |
| Gross Profit | CN¥1.58b |
| Other Expenses | CN¥1.10b |
| Earnings | CN¥482.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 03, 2025
| Earnings per share (EPS) | 1.12 |
| Gross Margin | 45.37% |
| Net Profit Margin | 13.85% |
| Debt/Equity Ratio | 4.0% |
How did 600993 perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 19:08 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mayinglong Pharmaceutical Group Co., Ltd. is covered by 15 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Liu | Changjiang Securities Co. LTD. |
| Ling Bo Tu | China Minzu Securities |
| Bing Zhao | China Renaissance Securities |